IOnctura Provides Development Update On First-In-Class Semi-Allosteric PI3Kδ Inhibitor Program
- Updated clinical data demonstrates a prolonged and sustained favorable safety profile for roginolisib (IOA-244)
- Clinical data shows a comparable safety profile in both solid and hematologic malignancies
- Clinical responses seen in both solid and hematologic malignancies
- US FDA grants Orphan Drug Designation for IOA-244 in uveal melanoma
Geneva, Switzerland and Amsterdam, The Netherlands, 5 January – iOnctura, a clinical-stage biotech developing selective cancer therapies against targets that play critical roles in multiple tumor survival pathways, today provides an update on IOA-244, its lead cancer drug, which is in development for solid and hematologic malignancies including uveal melanoma, a rare cancer arising within the uveal tract of the eye.